Abstract: Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells.

Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: Provided are chimeric receptors targeting NKG2D, and multispecific chimeric receptors comprising an NKG2D domain and a second antigen binding domain such as an IL-3 domain. Also provided are dual chimeric receptor systems comprising a first chimeric receptor comprising an NKG2D domain, and a second chimeric receptor comprising a second antigen binding domain such as an IL-3 domain. Further provided are engineered immune effector cells (such as T cells), pharmaceutical compositions, kits and methods of treating cancer.

Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.

Abstract: Provided herein are single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) having the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: Disclosed herein is a novel chimeric antigen receptor and use thereof. The novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. Nucleic acid sequences of various chimeric antigen receptors are separated and purified and provided is a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.

Abstract: A reactor tank is provided having an enzyme inlet, a heating jacket positioned around the exterior center of the tank, a gas outlet for communicating with a vacuum apparatus to create a vacuum within the reactor tank and for communicating with a condensing unit, a first gas inlet for receiving gas from a feed tank and a first liquid outlet for recirculating the liquid from the first liquid outlet back to the feed tank. The reactor tank further includes a sparged unit and a screen positioned within the tank between the sparged unit and the first liquid outlet, where the sparged unit is connected to the first gas inlet for receiving gas from the feed tank.

Abstract: The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.

Abstract: A reactor tank is provided having an enzyme inlet, a heating jacket positioned around the exterior center of the tank, a gas outlet communicating with a vacuum apparatus and a condensing unit, a first gas inlet for receiving gas from a feed tank and a first liquid outlet for recirculating the liquid back to the feed tank. The tank further includes a sparged unit connected to the first gas inlet for receiving gas from the feed tank and a screen positioned between the sparged unit and the first liquid outlet. The reactor tank is utilized in a reactor system further including a condensing unit, vacuum pump or venturi valve, a first feed tank, a coalescer having at least one circulation pipe and a first circulation pump.

Abstract: The present invention provides a cell-based platform for controllable, regionalized, and cost-effective delivery of immunomodulator and other therapeutic proteins, which is widely applicable in cancer immunotherapy.

Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: The invention relates to the utilization of fatty acid feedstocks with substantial free fatty acid content in the production of biodiesel by the use of microbial enzymes.

Abstract: A reactor tank is provided having an enzyme inlet, a heating jacket positioned around the exterior center of the tank, a gas outlet communicating with a vacuum apparatus and a condensing unit, a first gas inlet for receiving gas from a feed tank and a first liquid outlet for recirculating the liquid back to the feed tank. The tank further includes a sparged unit connected to the first gas inlet for receiving gas from the feed tank and a screen positioned between the sparged unit and the first liquid outlet. The reactor tank is utilized in a reactor system further including a condensing unit, vacuum pump or venturi valve, a first feed tank, a coalescer having at least one circulation pipe and a first circulation pump.

Abstract: The invention relates to the utilisation of fatty acid feedstocks with substantial free fatty acid content in the production of biodiesel by the use of microbial enzymes.